UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $285.29, but opened at $273.54. UCB shares last traded at $273.54, with a volume of 88 shares traded.

Analyst Ratings Changes

A number of research analysts have commented on UCBJF shares. Stephens restated an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Barclays reiterated an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday, February 16th. Finally, Wolfe Research initiated coverage on shares of UCB in a research report on Monday, February 23rd. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

UCB Trading Down 1.6%

The stock has a 50 day moving average of $302.60 and a two-hundred day moving average of $295.92. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.